RU2727474C2 - Виды комбинированной терапии для лечения рака - Google Patents

Виды комбинированной терапии для лечения рака Download PDF

Info

Publication number
RU2727474C2
RU2727474C2 RU2018109902A RU2018109902A RU2727474C2 RU 2727474 C2 RU2727474 C2 RU 2727474C2 RU 2018109902 A RU2018109902 A RU 2018109902A RU 2018109902 A RU2018109902 A RU 2018109902A RU 2727474 C2 RU2727474 C2 RU 2727474C2
Authority
RU
Russia
Prior art keywords
cancer
treatment
chlorophenyl
tumor
agents
Prior art date
Application number
RU2018109902A
Other languages
English (en)
Russian (ru)
Other versions
RU2018109902A3 (enExample
RU2018109902A (ru
Inventor
Реза Фатхи
Дрор БЕН-АШЕР
Даниелль АБРАМСОН
Original Assignee
Редхилл Байофарма Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Редхилл Байофарма Лтд. filed Critical Редхилл Байофарма Лтд.
Publication of RU2018109902A publication Critical patent/RU2018109902A/ru
Publication of RU2018109902A3 publication Critical patent/RU2018109902A3/ru
Application granted granted Critical
Publication of RU2727474C2 publication Critical patent/RU2727474C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2018109902A 2015-10-06 2016-10-06 Виды комбинированной терапии для лечения рака RU2727474C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562237925P 2015-10-06 2015-10-06
US62/237,925 2015-10-06
PCT/IB2016/001526 WO2017060771A2 (en) 2015-10-06 2016-10-06 Combination therapies for treating cancer

Publications (3)

Publication Number Publication Date
RU2018109902A RU2018109902A (ru) 2019-11-07
RU2018109902A3 RU2018109902A3 (enExample) 2020-03-05
RU2727474C2 true RU2727474C2 (ru) 2020-07-21

Family

ID=58446480

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018109902A RU2727474C2 (ru) 2015-10-06 2016-10-06 Виды комбинированной терапии для лечения рака

Country Status (12)

Country Link
US (4) US9844540B2 (enExample)
EP (1) EP3359255A4 (enExample)
JP (1) JP6963545B2 (enExample)
KR (1) KR20180058716A (enExample)
CN (1) CN108136207A (enExample)
AU (1) AU2016336133B2 (enExample)
BR (1) BR112018003232A2 (enExample)
CA (1) CA2997671A1 (enExample)
HK (1) HK1259342A1 (enExample)
MX (1) MX382754B (enExample)
RU (1) RU2727474C2 (enExample)
WO (1) WO2017060771A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4134076A1 (en) 2014-10-24 2023-02-15 Redhill Biopharma Ltd. Therapy for inhibition of single-stranded rna virus replication
WO2018195434A1 (en) 2017-04-21 2018-10-25 Lisanti Michael P Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
CA3060509A1 (en) 2017-04-21 2018-10-25 Federica Sotgia Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
KR20200010343A (ko) 2017-05-19 2020-01-30 루넬라 바이오테크 인코포레이티드 안티미토신: 암 줄기 세포를 근절하기 위한 미토콘드리아 생물발생의 표적화 억제제
WO2018213764A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
EP3644988B1 (en) 2017-06-26 2023-02-22 Lunella Biotech, Inc. Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells
JP2020534285A (ja) 2017-09-15 2020-11-26 アンパサンド バイオファーマシューティカルズ インコーポレイテッドＡｍｐｅｒｓａｎｄ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 投与および処置の方法
EP3681494A4 (en) * 2017-09-15 2021-08-04 Ampersand Biopharmaceuticals, Inc. INHIBITION OF SPONTANEOUS METASTASIS BY PROTEIN INHIBITORS OF CYSTEIN PROTEASES
BR112021013952A2 (pt) * 2019-01-16 2021-11-16 Apogee Biotechnology Corp Métodos de indução de uma resposta imunológica anticâncer
WO2020154716A1 (en) * 2019-01-26 2020-07-30 University Of Rochester Compositions and methods for treating prostate cancer
CA3174438A1 (en) * 2020-03-10 2021-09-16 Redhill Biopharma Ltd. Treatment of coronavirus infection
US11471448B2 (en) 2020-12-15 2022-10-18 Redhill Biopharma Ltd. Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
CN119700770A (zh) * 2025-01-09 2025-03-28 首都医科大学附属北京佑安医院 氯法齐明在制备修复肠黏膜或改善肠道菌群药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030013723A1 (en) * 1998-07-20 2003-01-16 Wilex Ag Novel urokinase inhibitors
US20040067952A1 (en) * 2001-07-17 2004-04-08 Morris David Lawson Method and composition for treatment of cancer
WO2013041963A2 (en) * 2011-09-20 2013-03-28 Redhill Biopharma Ltd A composition and method for treating an autoimmune disease
US20140314878A1 (en) * 2012-08-30 2014-10-23 James Sacchettini Compositions and methods for drug-sensitization or inhibition of a cancer cell

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2189001A1 (en) * 1994-04-26 1995-11-02 Nobuhiro Narita Medicinal composition as a remedy for nonsmall cell lung cancer
AUPP437698A0 (en) * 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
US6864264B1 (en) * 2002-08-20 2005-03-08 Gloria L. Anderson 1-adamantyl chalcones for the treatment of proliferative disorders
DE10323898A1 (de) * 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
DE102004057195A1 (de) * 2004-11-26 2006-06-01 Wilex Ag Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon
US20060142304A1 (en) * 2004-12-27 2006-06-29 Michael Southall Method for treating or preventing pruritic and neurogenic skin disorders
US20060270631A1 (en) * 2005-05-26 2006-11-30 Smith Charles D Methods for the treatment and prevention of angiogenic diseases
ES2528451T3 (es) * 2005-06-17 2015-02-10 Apogee Biothechnology Corporation Inhibidores de esfingosina cinasa
TWI405756B (zh) * 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
US20080226624A1 (en) * 2007-03-07 2008-09-18 Wolfgang Schmalix Combined treatment of cancer by urokinase inhibition and a cytostatic anti-cancer agent for enhancing the anti-metastatic effect
HRP20190045T1 (hr) * 2008-02-08 2019-03-08 Red Hill Biopharma Ltd. Metode i sastavi za liječenje upalne bolesti crijeva
EP4134076A1 (en) * 2014-10-24 2023-02-15 Redhill Biopharma Ltd. Therapy for inhibition of single-stranded rna virus replication

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030013723A1 (en) * 1998-07-20 2003-01-16 Wilex Ag Novel urokinase inhibitors
US20040067952A1 (en) * 2001-07-17 2004-04-08 Morris David Lawson Method and composition for treatment of cancer
WO2013041963A2 (en) * 2011-09-20 2013-03-28 Redhill Biopharma Ltd A composition and method for treating an autoimmune disease
US20140314878A1 (en) * 2012-08-30 2014-10-23 James Sacchettini Compositions and methods for drug-sensitization or inhibition of a cancer cell

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FRENCH K.J. et al. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2// The Journal of Pharmacology and Experimental Therapeutics, 08 Jan 2010, 333(1):129-139. *
FRORIEP D. et al. Activation of the anti-cancer agent upamostat by the mARC enzyme system// Xenobiotica. 2013 Sep;43(9):780-4. *
SAKAMOTO M. et al. Effect of clarithromycin treatment of natural killer cell activity in patients with advanced non-small cell lung cancer// Gan To Kagaku Ryoho. 1998 Dec;25(14):2259-66. *
SRI-PATHMANATHAN R.M. et al. Clofazimine alters the energy metabolism and inhibits the growth rate of a human lung‐cancer cell line in vitro and in vivo//Int J Cancer. 1994 Mar 15;56(6):900-5. *
SRI-PATHMANATHAN R.M. et al. Clofazimine alters the energy metabolism and inhibits the growth rate of a human lung‐cancer cell line in vitro and in vivo//Int J Cancer. 1994 Mar 15;56(6):900-5. SAKAMOTO M. et al. Effect of clarithromycin treatment of natural killer cell activity in patients with advanced non-small cell lung cancer// Gan To Kagaku Ryoho. 1998 Dec;25(14):2259-66. FRORIEP D. et al. Activation of the anti-cancer agent upamostat by the mARC enzyme system// Xenobiotica. 2013 Sep;43(9):780-4. *

Also Published As

Publication number Publication date
US20170095460A1 (en) 2017-04-06
CN108136207A (zh) 2018-06-08
MX382754B (es) 2025-03-13
US11633385B2 (en) 2023-04-25
WO2017060771A3 (en) 2017-07-06
RU2018109902A3 (enExample) 2020-03-05
JP6963545B2 (ja) 2021-11-10
KR20180058716A (ko) 2018-06-01
US20210128538A1 (en) 2021-05-06
HK1259342A1 (zh) 2019-11-29
MX2018004309A (es) 2018-05-22
US10463654B2 (en) 2019-11-05
EP3359255A2 (en) 2018-08-15
AU2016336133A1 (en) 2018-03-15
BR112018003232A2 (pt) 2018-09-25
AU2016336133B2 (en) 2021-02-25
US10946000B2 (en) 2021-03-16
CA2997671A1 (en) 2017-04-13
WO2017060771A2 (en) 2017-04-13
JP2018533560A (ja) 2018-11-15
US20200113881A1 (en) 2020-04-16
RU2018109902A (ru) 2019-11-07
EP3359255A4 (en) 2019-06-12
US9844540B2 (en) 2017-12-19
US20180125831A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
RU2727474C2 (ru) Виды комбинированной терапии для лечения рака
JP5075927B2 (ja) 固形腫瘍を予防および治療するための方法および組成物
JP6257326B2 (ja) 神経因性疼痛におけるマロノニトリルアミドの使用
KR20180126497A (ko) 치환된 아미노퓨린 화합물, 이의 조성물, 및 그것에 의한 치료 방법
PT1505973E (pt) Combinações para o tratamento de mieloma múltiplo
RU2519750C2 (ru) Способы лечения множественной миеломы
EA019919B1 (ru) Способ подавления роста или метастазирования ангиогенез-зависимой опухоли
TW201919616A (zh) 用於治療ｔ－ｐｌｌ的化合物
US20240366566A1 (en) Use of carbamate compound for prevention, alleviation or treatment of status epilepticus
CN113329749B (zh) 用于治疗葡萄膜黑色素瘤的联合疗法
JP6370801B2 (ja) 肝疾患または肝障害の治療のための使用および方法
WO2021048417A1 (en) Combination therapies comprising dasatinib for the treatment of cholangiocarcinoma
CN115969975B (zh) Phgdh抑制剂在预防和/或治疗结直肠癌转移中的应用
US20220409582A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
JP2015505313A (ja) 癌を治療するための併用療法
WO2021048419A1 (en) Combination therapies comprising trametinib for the treatment of cholangiocarcinoma
JP4686704B2 (ja) 動脈瘤予防および／または治療剤
RU2436572C2 (ru) Комбинация ингибиторов гистондеацетилазы и излучения
US20060009475A1 (en) Quinazolinone compounds in combined modalities for improved cancer treatment
JP2009108058A (ja) 抗リンパ腫組成物および方法